Pneumococcal Infections: all 286 studies

Page 2 of 3. Open to participants first (27), then studies with results posted, then the rest; newest registration first within each.

• Indirect Effects of Pneumococcal Vaccine on Nasopharyngeal CarriageCompletedNCT01311024Results posted
• Systems Biology of PNEUMOVAX®23 and PREVNAR 13®CompletedNCT01307449Not applicableResults posted
• A Study to Assess the Antibody Response of Healthy Chinese Children Who Have Been Vaccinated Previously With 4-doses of Prevenar (a Pneumococcal Vaccine) as Babies and ToddlersCompletedNCT01298544Phase 4Results posted
• A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003)CompletedNCT01215188Phase 2Results posted
• Safety and Tolerability Study for the Pneumococcal Conjugate Vaccine V114 Versus Prevnar™ (V114-001)CompletedNCT01215175Phase 1Results posted
• A Study To Assess The Safety And Effectiveness Of Prevenar In Chinese Children Who Have Not Previously Received A Vaccine Against Pneumococcal BacteriaCompletedNCT01193582Phase 4Results posted
• Immunization of Children Between 8 Weeks and 2 Years of Age With GSK Pneumococcal Vaccine GSK1024850ACompletedNCT01175083Phase 3Results posted
• Postlicensure Observational Safety Study of 13vPnC Administered to Infants and ToddlersCompletedNCT01128426Results posted
• Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPSCompletedNCT00963235Phase 3Results posted
• Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in HIV-Infected Subjects 6 Years of Age or Older Who Are Naive to Pneumococcal VaccineCompletedNCT00962780Phase 3Results posted
• Prevalence of Nasopharyngeal Carriage of Streptococcus Pneumoniae in Healthy Children of 12-18 Months in 6 Cities, ChinaCompletedNCT00952367Results posted
• Immune Response In Children Revaccinated With Pneumococcal Conjugate VaccineCompletedNCT00853749Phase 3Results posted
• Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in AdultsCompletedNCT00744263Phase 4Results posted
• Study Evaluating the Impact of the 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Alaskan Native Children.CompletedNCT00743652Phase 3Results posted
• Revaccination With PNEUMOVAX(TM) 23 in Older Adults (V110-007)CompletedNCT00560950Phase 3Results posted
• Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)CompletedNCT00546572Phase 3Results posted
• ZOSTAVAX™ Administered Concomitantly With PNEUMOVAX™ 23 (V211-012)(COMPLETED)CompletedNCT00535730Phase 3Results posted
• Study Evaluating the Impact of a 13-valent Pneumococcal Conjugate Vaccine on Nasopharyngeal ColonizationCompletedNCT00508742Phase 3Results posted
• Study Evaluating Safety of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Elderly SubjectsCompletedNCT00500266Phase 3Results posted
• Study Evaluating Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine With Influenza Vaccine in AdultsCompletedNCT00492557Phase 3Results posted
• Study Evaluating 7-Valent Pneumococcal Conjugate Vaccine in Healthy InfantsCompletedNCT00488826Phase 1Results posted
• Nasopharyngeal Streptococcus Pneumoniae CarriageCompletedNCT00471822Results posted
• COMPAS (Clinical Otitis Media & Pneumonia Study): Pneumonia & Acute Otitis Media (AOM ) Efficacy Study of the Pneumococcal Conjugate VaccineCompletedNCT00466947Phase 3Results posted
• Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in IndiaCompletedNCT00452790Phase 3Results posted
• Study Evaluating 13-valent Pneumococcal Conjugate Vaccine Catch-Up Regimens in Older Infants and ChildrenCompletedNCT00452452Phase 3Results posted
• Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in AdultsCompletedNCT00427895Phase 3Results posted
• Study Evaluating Pneumococcal Vaccine in Healthy InfantsCompletedNCT00205803Phase 1/2Results posted
• Immunogenicity and Reactogenicity of Pneumococcal Polysaccharide and Conjugate Vaccines in Native EldersCompletedNCT00153543Phase 1Results posted
• Clinical Trial of PCV24 in Adults Aged ≥18 YearsCompletedNCT07543198Phase 1/2
• Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal VaccinationActive, not recruitingNCT07425392Phase 3
• A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of AgeActive, not recruitingNCT07365826Phase 3
• PCV24 Clinical Trial in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 MonthsCompletedNCT07333352Phase 2
• Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49CompletedNCT07284654Phase 3
• A Clinical Trial to Observe the Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Target PopulationCompletedNCT07071701
• A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and InfantActive, not recruitingNCT07023081Phase 1
• A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese AdultsCompletedNCT07019909Phase 1
• A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)Active, not recruitingNCT07017777Phase 3
• Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and AdolescentsActive, not recruitingNCT06838000Phase 3
• Clinical Study on the Combined Administration of 15-Valent Pneumococcal Conjugate Vaccine and Diphtheria, Tetanus, Pertussis VaccineCompletedNCT06817187Phase 3
• Phase 2 Trial to Evaluate Safety and Immunogenicity of Inventprise's (IVT) 25-valent Pneumococcal Conjugate Vaccine (IVT PCV-25) in Healthy InfantsActive, not recruitingNCT06790290Phase 2
• A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy InfantsActive, not recruitingNCT06720038Phase 2
• Phase II Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate VaccineCompletedNCT06678620Phase 2
• Phase I Clinical Trial of PCV24 in People Aged 18 Years and OlderCompletedNCT06678607Phase 1
• Phase I Clinical Trial of PCV24 in Children Aged 2 Months (Minimum 6 Weeks) to 17 YearsCompletedNCT06675032Phase 1
• A Study to Learn About the Safety of PREVENAR 20 Vaccine in Infants Aged Between Two to Six MonthsActive, not recruitingNCT06622109
• Clinical Trial of PCV24 in Children Aged 2-17 YearsCompletedNCT06550830Phase 1
• A Study to Learn About How a New Pneumococcal Vaccine Works in ChildrenCompletedNCT06531538Phase 2
• A Study to Learn About How a New Pneumococcal Vaccine Works in InfantsActive, not recruitingNCT06524414Phase 2
• Clinical Trial of PCV24 in AdultsCompletedNCT06474377Phase 1
• A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate VaccineCompletedNCT06183216Phase 1
• A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in AdultsCompletedNCT06182124Phase 1/2
• A Phase I Study of XJ103 in Chinese Healthy SubjectsActive, not recruitingNCT06026748Phase 1
• Extension Safety and Immunogenicity Study of GPNV-001CompletedNCT05982314Phase 1/2
• A Phase 3 Study to Evaluate the Immunogenicity and Safety of Walvax's PCV13-TT as Compared to Pfizer's PCV13Active, not recruitingNCT05934890Phase 3
• Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy InfantsCompletedNCT05844423Phase 2
• A Study to Learn About a Type of Pneumococcal Vaccine With a New Ingredient (PF-07872411) Intended to Enhance the Effects of the Vaccine Which is Given to AdultsCompletedNCT05831124Phase 1
• Concomitant Administration of the Novavax Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Adults Aged ≥60 YearsStatus unknownNCT05767606Phase 4
• Phase III Clinical Trial of 13-valent Pneumococcal Conjugate Vaccine (Multivalent Conjugate) in InfantsActive, not recruitingNCT05759520Phase 3
• Lot-to-lot Consistency of 23-valent Pneumococcal Polysaccharide VaccineCompletedNCT05731115Phase 4
• Curian S. Pneumo/Legionella Assay Beta Clinical Trial ProtocolCompletedNCT05681156
• Safety, Tolerability and Immunogenicity of an Inactivated Whole-cell Pneumococcal Vaccine Gamma-PN3.CompletedNCT05667740Phase 1
• Phase I Clinical Trial of a Candidate PCV13 in Healthy PeopleStatus unknownNCT05602480Phase 1
• A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and TaiwanCompletedNCT05512819Phase 3
• Immunogenicity and Safety of 23-valent Pneumococcal Polysaccharide VaccineCompletedNCT05477693Phase 4
• Serotype Distribution in Hospitalized Adult With Pneumococcal Community Acquired Pneumonia in FranceCompletedNCT05380193
• A Controlled Human Pneumococcal Infection Model (PIM) StudyCompletedNCT05361499Not applicable
• Impact of Pharmacist-led Educational Intervention on Pneumococcal Vaccination Rates in Cancer PatientsCompletedNCT05229081Not applicable
• Pneumococcal Vaccination in Patients With Chronic Lymphocytic LeukaemiaStatus unknownNCT05145101
• Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate VaccineCompletedNCT05092386Phase 1
• Prevention of Pneumococcal Infections: Impact Collaborative Medico-pharmaceutical Care Structured to Improve Vaccination Coverage of Patients at Risk.CompletedNCT05060146Not applicable
• A Clinical Trial of 23-valent Pneumococcal Polysaccharide VaccineCompletedNCT04989465Phase 4
• Evaluating the Effectiveness of a Pneumococcal Immunisation Campaign in a Camp for Internally Displaced PeopleActive, not recruitingNCT04945681Phase 4
• Pneumococcal Nasopharyngeal Colonization as Predictor of Community-Acquired Pneumonia (CAP) in Adults With Chronic Diseases.Status unknownNCT04944719
• Immunogenicity After Revaccination With 23-valent Pneumococcal Polysaccharide Vaccine: Healthy Elderly People Versus Diabetic PatientsStatus unknownNCT04875858Phase 4
• Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i)CompletedNCT04841369Phase 3
• Safety and Immunogenicity of the 'EuPCV15' in Healthy Korean AdultsCompletedNCT04830358Phase 1
• A Study to Assess the Safety, Tolerability and Immunogenicity of ASP3772, a Pneumococcal Vaccine, in Toddlers 12 to 15 Months of Age in Comparison to an Active ComparatorCompletedNCT04525599Phase 1
• An Epidemiological Survey to Establish the Spectrum of Circulating Serotypes of S. Pneumoniae, in Patients Older 18 YearsCompletedNCT04464291Not applicable
• Evaluation of Prime-boost Anti-pneumococcal Vaccination in Patients With Diffuse Large B Cell Lymphoma Treated With RituximabCompletedNCT04214444Phase 3
• PCV13 in Non-pregnant Papua New Guinean WomenCompletedNCT04183322
• Phase I Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and AboveCompletedNCT04100772Phase 1
• Surveillance of Invasive Pneumococcal Infections in Adults (Excluding Meningitis)CompletedNCT03983616
• Revaccination With PPS23 Boosted or Not by PCV13 in Splenectomised Patients.CompletedNCT03873727Phase 2
• What is the Incidence of an Immune Disorder in Children With Invasive Pneumococcal Disease (IPD)?CompletedNCT03815357
• Impact of HIV-1 and Aging on Mucosal Vaccine ResponsesActive, not recruitingNCT03729778Early Phase 1
• Determination of the Utility of Pfizer's Pneumococcal Urine Antigen Test in Children 5 Years of Age or Younger With Community Acquired Pneumonia in GuatemalaCompletedNCT03696303
• Trial to Evaluate the Safety and Immunogenicity of Multivalent Pneumococcal Vaccines in Japanese Adults 18 to 49 Years of AgeCompletedNCT03642847Phase 1
• Pneumococcal Vaccination of Multiple Myeloma Patients on Novel AgentsCompletedNCT03619252Phase 4
• Immunogenicity and Safety of a Tetanus-diphtheria Vaccine and a 13-valent Pneumococcal Conjugate VaccineCompletedNCT03552445Phase 4
• A Study to Evaluate the Safety and Immunogeneicity of Multivalent Pneumococcal Conjugate Vaccine in Healthy AdultsStatus unknownNCT03549208Phase 1
• The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines on Immunogenicity and Carriage in Kenyan InfantsCompletedNCT03489018Phase 4
• A Study to Evaluate the Safety and Immunogenecity of LBVE(Multivalent Pneumococcal Conjugate Vaccine) in Healthy InfantsCompletedNCT03467984Phase 2
• CIRN Pneumococcal Conjugate Vaccine 1 vs. 2 Dose Priming StudyCompletedNCT03384589Phase 2/3
• Mobile Phone SMS Messages and Automated Calls in Improving Vaccine Coverage Among Children in PakistanStatus unknownNCT03341195Not applicable
• Understanding Pneumococcal Carriage and Disease 2017-2020Status unknownNCT03102840
• Pneumococcal Vaccination for Splenectomised Thalassemia Major Patients in IndonesiaCompletedNCT03095326Phase 4
• Systematic Search for Primary Immunodeficiency in Adults With InfectionsCompletedNCT02972281Not applicable
• A Phase 1, Randomized, Controlled, Observer-blinded Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Healthy Adults Aged 18 to 49 YearsCompletedNCT02955160Phase 1
• Immunogenicity and Safety Study of NBP606 in Healthy ToddlersCompletedNCT02927444Phase 3
• A Phase I Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine and 14-valent Pneumococcal Conjugate Vaccine in AdultsCompletedNCT02892812Phase 1

← Pneumococcal Infections overview